Wedbush Reiterates “Outperform” Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research note issued on Tuesday, Benzinga reports. They currently have a $10.00 price objective on the stock. Wedbush’s price objective indicates a potential upside of 35.50% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 7th.

TScan Therapeutics Trading Up 1.7 %

Shares of TCRX opened at $7.38 on Tuesday. The company has a market capitalization of $353.35 million, a P/E ratio of -3.90 and a beta of 0.90. TScan Therapeutics has a one year low of $1.62 and a one year high of $9.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.51 and a current ratio of 6.51. The stock has a 50-day moving average price of $7.14 and a 200 day moving average price of $5.78.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. The firm had revenue of $7.21 million during the quarter, compared to the consensus estimate of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. Sell-side analysts forecast that TScan Therapeutics will post -1.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TCRX. Letko Brosseau & Associates Inc. bought a new position in TScan Therapeutics during the 3rd quarter worth approximately $83,000. Pale Fire Capital SE acquired a new stake in shares of TScan Therapeutics during the 3rd quarter worth approximately $42,000. abrdn plc acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth approximately $1,166,000. Finally, Cannon Global Investment Management LLC acquired a new stake in shares of TScan Therapeutics during the 1st quarter worth approximately $139,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.